We claim:

1. A pharmaceutical combination, comprising a histamine-3 receptor inverse agonist and an acetylcholinesterase inhibitor; wherein the histamine-3 receptor inverse agonist is selected from the group consisting of:
N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide;
N-[4-(1-Cyclopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide; and
N-[4-(1-Isopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide;
or a pharmaceutically acceptable salt thereof;
and the acetylcholinesterase inhibitor is selected from the group consisting of donepezil, rivastigmine, galantamine and a pharmaceutically acceptable salt thereof.

2. The pharmaceutical combination as claimed in claim 1, wherein the histamine-3 receptor inverse agonist is N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof.

3. The pharmaceutical combination as claimed in claim 1, wherein the pharmaceutically acceptable salt of the histamine-3 receptor inverse agonist is selected from the group consisting of
N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride;
N-[4-(1-Cyclopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide tartrate; and
N-[4-(1-Isopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide tartrate.

4. The pharmaceutical combination as claimed in any one of claims 1 to 3, wherein the histamine-3 receptor inverse agonist is N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride.

5. The pharmaceutical combination as claimed in any one of claims 1 to 4, wherein the acetylcholinesterase inhibitor is donepezil or a pharmaceutically acceptable salt thereof.

6. The pharmaceutical combination as claimed in any one of claims 1 to 5, wherein the acetylcholinesterase inhibitor is donepezil hydrochloride.

7. A pharmaceutical combination, comprising N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride and donepezil hydrochloride.

8. The pharmaceutical combination as claimed in any one of claims 1 to 7, for use in therapy.

9. Use of the pharmaceutical combination as claimed in any one of claims 1 to 7 in the manufacture of a medicament for the treatment of cognitive disorders in a patient.

10. The use as claimed in claim 9, wherein the cognitive disorder is selected from the group consisting of Alzheimer's disease, schizophrenia, Parkinson's disease, Lewy body dementia, vascular dementia, frontotemporal dementia, Down syndrome and Tourette's syndrome.

11. A compound, N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl) acetamide or a pharmaceutically acceptable salt thereof in a pharmaceutical combination with an acetylcholinesterase inhibitor for use in therapy;
wherein the acetylcholinesterase inhibitor is selected from the group consisting of donepezil, rivastigmine, galantamine and a pharmaceutically acceptable salt thereof.

12. The compound for use as claimed in claim 11, as an adjunct treatment for Alzheimer's disease in a patient on stable treatment with the acetylcholinesterase inhibitor.

13. Use of N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof and an acetylcholinesterase inhibitor in the manufacture of a medicament for the treatment of Alzheimer's disease in a patient;
wherein the acetylcholinesterase inhibitor is selected from the group consisting of donepezil, rivastigmine, galantamine and a pharmaceutically acceptable salt thereof.

14. Use of N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of Alzheimer's disease in a patient on stable treatment with an acetylcholinesterase inhibitor;
wherein the acetylcholinesterase inhibitor is selected from the group consisting of donepezil, rivastigmine, galantamine and a pharmaceutically acceptable salt thereof.

15. The use as claimed in claim 13 or claim 14, wherein the pharmaceutically acceptable salt of N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide is N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride.

16. The use as claimed in any one of claims 13 to 15, wherein 0.1 mg to 100 mg of N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof is to be administered to the patient per day.

17. The use as claimed in any one of claims 13 to 16, wherein 0.1 mg to 60 mg of N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof is to be administered to the patient per day.

18. The use as claimed in any one of claims 13 to 17, wherein 0.1 mg to 30 mg of N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof is to be administered to the patient per day.

19. The use as claimed in any one of claims 13 to 18, wherein 1 mg to 30 mg of donepezil, or a pharmaceutically acceptable salt thereof is to be administered to the patient per day.

20. A pharmaceutical composition, comprising the pharmaceutical combination as claimed in any one of claims 1 to 7, and pharmaceutically acceptable excipients or a combination thereof.

21. The pharmaceutical composition as claimed in claim 20, for use in therapy.

22. Use of the pharmaceutical composition as claimed in claim 20 in the manufacture of a medicament for the treatment of cognitive disorders selected from the group consisting of Alzheimer's disease, schizophrenia, Parkinson's disease, Lewy body dementia, vascular dementia, frontotemporal dementia, Down syndrome and Tourette's syndrome.

23. The pharmaceutical composition as claimed in claim 20, wherein the histamine-3 receptor inverse agonist is N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof and is present in an amount of 0.1 mg to 100 mg.

24. The pharmaceutical composition as claimed in claim 20 or claim 23, wherein the histamine-3 receptor inverse agonist is N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof and is present in an amount of 0.1 mg to 60 mg.

25. The pharmaceutical composition as claimed in any one of claims 20, 23 and 24, wherein the histamine-3 receptor inverse agonist is N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof and is present in an amount of 0.1 mg to 30 mg.

26. The pharmaceutical composition as claimed in any one of claims 20 and 23 to 25, wherein the acetylcholinesterase inhibitor is donepezil or a pharmaceutically acceptable salt thereof and is present in an amount of 2 mg to 30 mg.

27. The use as claimed in claim 13, wherein the N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof is to be administered to the patient by oral, nasal, local, dermal or parenteral routes.

28. The use as claimed in claim 13, wherein the N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof is to be administered to the patient one to three times per day, one to three times per week or one to three times per month.